| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 67.8% | 68.5% | ▲ +0.7% |
| Healthcare Services | 17.9% | 17.5% | ▼ -0.4% |
| Insurance | 7.3% | 7.3% | ● 0.0% |
| Retailing | 1.6% | 1.7% | ● +0.0% |
| IT - Services | 1.6% | 1.5% | ● 0.0% |
| Healthcare Equipment & Supplies | 1.1% | 1.0% | ▼ -0.1% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 68.5% | 72.7% | ▲ +4.2% |
| Healthcare Services | 17.5% | 17.2% | ▼ -0.3% |
| Insurance | 7.3% | 5.4% | ▼ -1.8% |
| IT - Services | 1.5% | 1.5% | ● 0.0% |
| Retailing | 1.7% | 1.2% | ▼ -0.5% |
| Healthcare Equipment & Supplies | 1.0% | 0.0% | ▼ -1.0% |
Comparing May 2026 → Jun 2026
| # | Stock | Sector | Last Weight (May 2026) |
|---|---|---|---|
| 1 | ICICI Prudential Life Insurance Company Limited ₹14.61 Cr |
Insurance | 2.69% |
| 2 | Poly Medicure Limited ₹5.14 Cr |
Healthcare Equipment & Supplies | 0.95% |
| # | Stock | Sector | May 2026 | Jun 2026 | Change |
|---|---|---|---|---|---|
| 1 | Mankind Pharma Limited ₹16.55 Cr |
Pharmaceuticals & Biotechnology | 0.03% | 2.99% | +2.96% |
| 2 | Divi's Laboratories Limited ₹29.61 Cr |
Pharmaceuticals & Biotechnology | 3.68% | 5.35% | +1.67% |
| 3 | Max Financial Services Limited ₹12.43 Cr |
Insurance | 1.22% | 2.25% | +1.03% |
| 4 | Lupin Limited ₹36.29 Cr |
Pharmaceuticals & Biotechnology | 5.83% | 6.56% | +0.73% |
| 5 | Gland Pharma Limited ₹6.24 Cr |
Pharmaceuticals & Biotechnology | 0.41% | 1.13% | +0.72% |
| 6 | IPCA Laboratories Limited ₹32.11 Cr |
Pharmaceuticals & Biotechnology | 5.18% | 5.80% | +0.62% |
| 7 | Glenmark Pharmaceuticals Limited ₹17.63 Cr |
Pharmaceuticals & Biotechnology | 2.61% | 3.19% | +0.58% |
| 8 | Laurus Labs Limited ₹34.90 Cr |
Pharmaceuticals & Biotechnology | 5.76% | 6.31% | +0.55% |
| 9 | Zydus Lifesciences Limited ₹13.91 Cr |
Pharmaceuticals & Biotechnology | 1.98% | 2.51% | +0.53% |
| 10 | Ajanta Pharma Limited ₹10.78 Cr |
Pharmaceuticals & Biotechnology | 1.61% | 1.95% | +0.34% |
| # | Stock | Sector | May 2026 | Jun 2026 | Change |
|---|---|---|---|---|---|
| 1 | Abbott India Limited ₹11.45 Cr |
Pharmaceuticals & Biotechnology | 5.43% | 2.07% | -3.36% |
| 2 | Sun Pharmaceutical Industries Limited ₹41.91 Cr |
Pharmaceuticals & Biotechnology | 9.09% | 7.58% | -1.51% |
| 3 | Aster DM Healthcare Limited ₹13.34 Cr |
Healthcare Services | 3.15% | 2.41% | -0.74% |
| 4 | Procter & Gamble Health Limited ₹3.16 Cr |
Pharmaceuticals & Biotechnology | 1.22% | 0.57% | -0.65% |
| 5 | MedPlus Health Services Limited ₹6.49 Cr |
Retailing | 1.65% | 1.17% | -0.48% |
| 6 | AstraZeneca Pharma India Limited ₹21.39 Cr |
Pharmaceuticals & Biotechnology | 4.12% | 3.87% | -0.25% |
| 7 | SBI Life Insurance Company Limited ₹17.66 Cr |
Insurance | 3.36% | 3.19% | -0.17% |
| 8 | Cipla Limited ₹5.86 Cr |
Pharmaceuticals & Biotechnology | 1.16% | 1.06% | -0.10% |
| 9 | Inventurus Knowledge Solutions Limited ₹8.40 Cr |
IT - Services | 1.54% | 1.52% | -0.02% |
| 10 | Metropolis Healthcare Limited ₹7.02 Cr |
Healthcare Services | 1.28% | 1.27% | -0.01% |
31 stocks — Jun 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹41.91 Cr |
Pharmaceuticals & Biotechnology |
7.58%
|
|
| 2 |
₹36.29 Cr |
Pharmaceuticals & Biotechnology |
6.56%
|
|
| 3 |
₹34.90 Cr |
Pharmaceuticals & Biotechnology |
6.31%
|
|
| 4 |
₹32.11 Cr |
Pharmaceuticals & Biotechnology |
5.80%
|
|
| 5 |
₹30.03 Cr |
Pharmaceuticals & Biotechnology |
5.43%
|
|
| 6 |
₹29.61 Cr |
Pharmaceuticals & Biotechnology |
5.35%
|
|
| 7 |
₹26.91 Cr |
Healthcare Services |
4.87%
|
|
| 8 |
₹25.25 Cr |
Pharmaceuticals & Biotechnology |
4.57%
|
|
| 9 |
₹23.92 Cr |
Healthcare Services |
4.32%
|
|
| 10 |
₹21.39 Cr |
Pharmaceuticals & Biotechnology |
3.87%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.